Fusion Pharmaceuticals Inc., a Canadian-born company developing targeted alpha-particle radiotherapeutics to treat cancer, has completed an oversubscribed $105 million series B financing led by Varian Medical Systems Inc. and new investor Orbimed. The company said the funds will be used to advance and broaden the scope of its ongoing clinical program and accelerate a pipeline of new radiopharmaceuticals and combination therapies.